Deep Lens Survey

Rev1 Ventures Launches $30 Million Fund, the Third to Support Research-Based Healthcare Innovation

Retrieved on: 
Tuesday, September 19, 2023
Knowledge, Vaccine, Ohio State University, Therapy, Nationwide Children's Hospital, Columbus metropolitan area, Ohio, Biotechnology, Innovation, Research, Deep Lens Survey, Neuroscience, Hospital, Biofilm, Pharmaceutical industry

COLUMBUS, Ohio, Sept. 19, 2023 /PRNewswire-PRWeb/ -- Today, Rev1 Ventures, the venture studio that helps entrepreneurs and corporations accelerate innovation, Nationwide Children's Hospital, and The Ohio State University announce expanded support for life sciences companies with the launch of Rev1 Catalyst Fund III, a $30 million fund that delivers capital and strategic services for pre-seed, seed stage and early-stage healthcare innovators.

Key Points: 
  • Following the success of Rev1 Catalyst Fund II , Rev1 NCH Fund, and Rev1 Catalyst Fund, this fund will remain focused on core research-based themes, including gene and cell therapy, neuroscience, biofilms, ocular health, cardiovascular health, and other therapeutics technologies.
  • Rev1 Catalyst Fund and Rev1 NCH Fund have generated more than $450 million in exits, including the acquisitions of Celenex , Myonexus , and Deep Lens .
  • "This fund will support groundbreaking advancements and help build successful companies that are working to positively impact people's lives."
  • For more information about the fund and Rev1 Ventures, visit https://www.rev1ventures.com/our-companies/ .

Deep Lens and Hematology-Oncology Associates of Central New York Collaborate to Improve Clinical Trial Matching for Oncology Patients

Retrieved on: 
Wednesday, January 12, 2022
Managed Care, Software, Research, Pharmaceutical, Data Management, Oncology, Technology, Hospitals, Clinical Trials, Science, Practice Management, Health, Other Science, National Cancer Institute, Patient, Technology, Nursing, Research, Foundation Medicine, Helmy Eltoukhy, Clinical trial, Lens, Adoption, Population, Therapy, Social, Pharmacist, VIPER, Diagnosis, Degenerative disease, Pathology, Cancer, EMR, Deep Lens Survey, CNY, Practitioner, Organization, Partnership, Pharmaceutical industry, Medical imaging, Medicine, Central New York, HOA, MD, Hematology-Oncology Associates of Central New York, Deep Lens, HEMATOLOGY-ONCOLOGY ASSOCIATES OF CENTRAL NEW YORK, DEEP LENS

Deep Lens and Hematology-Oncology Associates of Central New York (HOA CNY) today announced that they have entered into a collaboration to expand the clinical trial program and improve trial matching capabilities for the upstate New York-based practice.

Key Points: 
  • Deep Lens and Hematology-Oncology Associates of Central New York (HOA CNY) today announced that they have entered into a collaboration to expand the clinical trial program and improve trial matching capabilities for the upstate New York-based practice.
  • Deep Lens is a digital healthcare company that utilizes proprietary artificial intelligence-based technology solutions and other services to help improve efficiencies related to clinical trial recruitment and enrollment.
  • It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, fewer than 1 in 30 patients participate in a clinical trial.
  • Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.

Force Therapeutics Appoints Greg Andreola as New Chief Revenue Officer

Retrieved on: 
Friday, December 17, 2021
Organization, Therapy, Solution, Isenberg School of Management, Biology, Diagnosis, Industry, Assumption College, Acquisition, Deep Lens Survey, Philips, Research, Marketing, CEO, Patient, Leadership, Multimedia, MBA, Force, University of Massachusetts, University, Partnership, CRO, View, Pharmaceutical industry, Management

NEW YORK, Dec. 17, 2021 /PRNewswire/ -- Force Therapeutics, the leading patient engagement platform and research network, announced today that Greg Andreola has joined its leadership team as chief revenue officer.

Key Points: 
  • NEW YORK, Dec. 17, 2021 /PRNewswire/ -- Force Therapeutics, the leading patient engagement platform and research network, announced today that Greg Andreola has joined its leadership team as chief revenue officer.
  • After a year of record growth in the number of patients and providers using its episode of care management platform, Force appointed Andreola to oversee revenue generation and further the company's performance momentum.
  • "Greg comes to us with more than 20 years of commercial leadership experience in the healthcare space.
  • Andreola most recently served as chief revenue officer at Deep Lens, an AI company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of diagnosis.

Deep Lens Announces Launch of Real Time Feasibility Offering to Assist in Oncology Clinical Trial Design and Site Selection

Retrieved on: 
Tuesday, December 7, 2021
Data Management, Other Health, Technology, Pharmaceutical, Practice Management, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Physician, Precision medicine, EMR, CRO, Medicine, JAMA, Socialist Unity Network, Data analysis, Patient, Journal, Biomarker, American Medical Association, Cancer, Area studies, Lens, Vision, Clinical trial, Deep Lens Survey, Diagnosis, AI, VIPER, Medical imaging, Pharmaceutical industry, Deep Lens, Precision for Medicine, DEEP LENS, PRECISION FOR MEDICINE

Site selection is critical to ensuring on-time accrual; however, traditional feasibility studies rely on physicians estimating enrollment based on the number of patients seen in their clinical practice.

Key Points: 
  • Site selection is critical to ensuring on-time accrual; however, traditional feasibility studies rely on physicians estimating enrollment based on the number of patients seen in their clinical practice.
  • For more information about the Real Time Feasibility Offering or other Deep Lens services, please visit: www.deeplens.ai/real-time-feasibilty-dashboard .
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.
  • Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences.

Deep Lens and Southern Oncology Specialists Enter Strategic Partnership That Will Use AI-Based Solution VIPER™ to Improve Clinical Trial Matching

Retrieved on: 
Thursday, October 28, 2021
Data Management, Other Health, Technology, Pharmaceutical, Physical Therapy, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Research, Technology, Diagnosis, Cancer, Disease, Innovation, ICOP, Pathology, CLIA, Partnership, Patient, Helmy Eltoukhy, VIPER, Foundation Medicine, Time, Precision medicine, Clinical trial, EMR, Population, Deep Lens Survey, Tempus, Medical imaging, Southern Oncology Specialists, Deep Lens, SOUTHERN ONCOLOGY SPECIALISTS, DEEP LENS

Southern Oncology Specialists and Deep Lens today announced that they have entered into a strategic agreement that will use Deep Lens artificial intelligence (AI) based technology and other services to expand the practices clinical trial offering to patients.

Key Points: 
  • Southern Oncology Specialists and Deep Lens today announced that they have entered into a strategic agreement that will use Deep Lens artificial intelligence (AI) based technology and other services to expand the practices clinical trial offering to patients.
  • Southern Oncology Specialists offers comprehensive cancer care and serves patients in four locations in the greater Charlotte region.
  • Deep Lens is a digital healthcare company that uses AI to accelerate clinical trial recruitment and enrollment for community oncology practices.
  • The Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.

Deep Lens and Ocala Oncology/Florida Cancer Affiliates Collaborate to Expand Clinical Research Program with AI-Based Trial Matching Solution

Retrieved on: 
Wednesday, October 20, 2021
Data Management, Other Health, Technology, Pharmaceutical, Practice Management, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Clinical trial, Innovation, EMR, MD, Hematology, Diagnosis, Pathology, Research, Foundation Medicine, Patient, Partnership, Deep Lens Survey, Population, Cancer, ICOP, VIPER, Helmy Eltoukhy, Medical imaging, Ocala Oncology/Florida Cancer Affiliates, Deep Lens, OCALA ONCOLOGY/FLORIDA CANCER AFFILIATES, DEEP LENS

Ocala Oncology/ Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice.

Key Points: 
  • Ocala Oncology/ Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice.
  • Ocala Oncology/Florida Cancer Affiliates specializes in hematology and oncology care and serves patients in the Central Florida area.
  • Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

Deep Lens and Pacific Cancer Care Enter Strategic Partnership to Improve Clinical Trial Matching for Oncology Patients

Retrieved on: 
Friday, October 8, 2021
Software, Oncology, General Health, Health, Data Management, Technology, Genetics, Clinical Trials, University of California, Davis, Hematology, Acceleration, UCSF, Time, Diagnosis, Stanford University, Cancer, Dana–Farber Cancer Institute, Population, Helmy Eltoukhy, UC, Foundation Medicine, Central Coast (California), Deep Lens Survey, Pathology, Knowledge, Solution, VIPER, EMR, Partnership, Clinical trial, Patient, Disease, Medical imaging, Pharmaceutical industry, Pacific Cancer Care, Deep Lens, PACIFIC CANCER CARE, DEEP LENS

Pacific Cancer Care and Deep Lens today announced that they are collaborating to optimize clinical trial matching and accelerate enrollment at the Monterey-based practice through the use of Deep Lens artificial-intelligence (AI) based solutions and other services.

Key Points: 
  • Pacific Cancer Care and Deep Lens today announced that they are collaborating to optimize clinical trial matching and accelerate enrollment at the Monterey-based practice through the use of Deep Lens artificial-intelligence (AI) based solutions and other services.
  • This partnership will expand Pacific Cancer Cares existing clinical trial offering to patients by more accurately and effectively identifying eligible patients for trials, improving communications between patient care teams and bringing more trials to the practice.
  • It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, fewer than 1 in 30 patients participate in a clinical trial.
  • Pacific Cancer Care has provided superior care for patients, including innovative state of the art clinical trials, for nearly 50 years.

Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 28, 2021
Food, Goal, Clinical trial, Securities Act of 1933, Probability, VIPER, Diagnosis, Risk, Precision medicine, Annual report, Therapy, Security (finance), Drug Quality and Security Act, Tobacco, NASDAQ, U.S. Securities and Exchange Commission, FDA, Cancer, Patient, Magic Lantern (firmware), Field triage, Lung cancer, NSCLC, Marketing, CEO, Computational biology, Deep Lens Survey, EMR, Large-cell lung carcinoma, Humanitarian use licenses, COVID-19, Judgement, American Cancer Society, A.I, ADC, Research, Drug development, Safety, Securities Exchange Act of 1934, Machine learning, GlobalData, SEC, Non-Smokers' Rights Association, Pharmaceutical industry, Medical imaging

enabled drug development pathway that is expected to accelerate trial enrollment for Lantern's planned Phase 2 clinical trial for never-smokers with non-small cell lung cancer (NSCLC), utilizing LP-300 in combination with chemotherapy.

Key Points: 
  • enabled drug development pathway that is expected to accelerate trial enrollment for Lantern's planned Phase 2 clinical trial for never-smokers with non-small cell lung cancer (NSCLC), utilizing LP-300 in combination with chemotherapy.
  • Deep Lens' proprietary A.I.-based platform, VIPER, identifies, triages and matches cancer patients to clinical trials in real time for which they may be eligible.
  • For this reason, we are very excited to partner with Deep Lens and create an end-to-end A.I.
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices

Retrieved on: 
Thursday, September 16, 2021
Technology, Research, Genetics, Clinical Trials, Software, Health, Pharmaceutical, Science, Oncology, Precision medicine, Immunotherapy, Pathology, Knowledge, Science, Radiology, CEO, Complex, Drug development, EMR, Patient, Pressure, CRO, Safety, Deep Lens Survey, Therapy, Deep, Multimedia, VIPER, Partnership, Hospital, Diagnosis, Time, Research, Cancer, Medical imaging, Pharmaceutical industry, TD2, Deep Lens, TD2, DEEP LENS

Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will enhance access to tailored oncology treatments and novel clinical studies for patients receiving care in community oncology practices.

Key Points: 
  • Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will enhance access to tailored oncology treatments and novel clinical studies for patients receiving care in community oncology practices.
  • The partnership will enable TD2 to offer Deep Lens proprietary clinical trial matching solution, VIPER, as well as other research coordination services, to its drug development clients, thereby improving the ability for hospitals, trial coordinators, investigators, and patients to promote, collaborate, participate in and manage oncology clinical trials.
  • The highest priority for TD2 is to ensure every patient that participates in a TD2 clinical trial has the opportunity of achieving clinical benefit, said Stephen Gately, President and CEO at TD2.
  • Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the best therapies.

Beverly Hills Cancer Center and Deep Lens Partner to Integrate Novel AI-based Clinical Trial Matching Solution VIPER™ Into Practice, Expanding Offering to Patients

Retrieved on: 
Thursday, September 9, 2021
Research, Technology, Clinical Trials, Software, Pharmaceutical, Health, Data Management, Science, Oncology, Other Science, Beverly Hills Cancer Center, Deep Lens, BEVERLY HILLS CANCER CENTER, DEEP LENS

Beverly Hills Cancer Center and Deep Lens today announced a strategic collaboration that will deploy Deep Lens AI-based clinical trial matching solution VIPER and other services into one of Southern Californias few private cancer centers.

Key Points: 
  • Beverly Hills Cancer Center and Deep Lens today announced a strategic collaboration that will deploy Deep Lens AI-based clinical trial matching solution VIPER and other services into one of Southern Californias few private cancer centers.
  • As part of this partnership, Beverly Hills Cancer Center will be able to accelerate clinical trial enrollment and broaden its already robust clinical research program and offering to patients.
  • Beverly Hills Cancer Center already has an exceptional clinical research program and we are delighted to partner with them to assist in growing their current offering, said Greg Andreola, chief revenue officer of Deep Lens.
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.